Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status by Loman, Niklas et al.
Introduction
The influence of hereditary factors over breast cancer risk
in women is well established. In a review and meta-analy-
sis of previously published case–control and cohort
studies, Pharoah and colleagues concluded in 1997 that a
woman with a relative with breast cancer has an approxi-
mately doubled breast cancer risk compared with con-
trols. The risk of breast cancer tended to be higher in first-
degree relatives (FDRs) of affected individuals than in
second-degree relatives, tended to be higher if there was
more than one close relative with breast cancer, and
tended to be higher if the affected woman was younger
BRCA1 = breast cancer susceptibility gene 1; BRCA2 = breast cancer susceptibility gene 2; BRCA = both breast cancer susceptibility gene 1
and breast cancer susceptibility gene 2; CI = confidence interval; FDR = first-degree relative; NHL = non-Hodgkin’s lymphoma; SIR = standardized
incidence ratio.
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Abstract
Background Relatives of breast cancer cases have an
increased risk of the disease. The risk increases with increasing
numbers and decreasing age of onset of affected relatives. In
families with a BRCA1 or a BRCA2 mutation, individual carrier
status predicts the risk of breast cancer. In relatives of cases
where both BRCA1 and BRCA2 mutations are excluded, the
risk remains undetermined.
Methods Standardized incidence ratios (SIRs) and cumulative
cancer incidences were calculated for relatives of a population-
based set of early-onset breast cancer index cases (younger
than age 41 years) with a defined BRCA mutation status
(n=203).
Results In first-degree relatives (FDRs) of mutation-negative
cases, breast cancer incidences (SIR=2.3), prostate cancer
incidences (SIR=1.7), cervix cancer incidences (SIR=3.3)
and nonmelanoma skin cancer incidences (SIR=2.8) were
increased. The risks of breast cancer, prostate cancer and
nonmelanoma skin cancer were further increased in FDRs of
breast cancer cases younger than 36 years of age. In high-risk
individuals with at least one relative with breast cancer apart
from the index case, but no BRCA mutation in the family, breast
cancer incidence was increased (SIR=5.3); again the prostate
cancer incidence was elevated (SIR=2.5). The cumulative
incidence of breast cancer at ages 50 and 70 years for FDRs
of index cases without a BRCA mutation was 3.6% and
12.8%, respectively. Similarly, the cumulative incidence of
breast cancer for high-risk women was 6.3% and 21.1% at
ages 50 and 70 years, and that for FDRs of BRCA mutation
carriers was 17.2% and 27.7% at the same ages.
Conclusion The incidence of breast cancer is increased for FDRs
of women with early-onset breast cancer irrespective of the
BRCA status in the family. Risk increases with decreasing age
and with increasing number of affected relatives. The incidences
of prostate cancer, cervix cancer and nonmelanoma skin cancer
are elevated for FDRs of early-onset breast cancer cases without
a  BRCA mutation, indicating a possible association between
these cancers and early-onset breast cancer.
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than 50 years at the time of diagnosis compared with if
she was older than 50 years [1]. Similar data have been
reported from a Swedish population [2].
Epidemiologically based data from different cohort and
case–control studies of different populations have been
used to create risk models that are applied clinically in
oncogenetic counselling. The two most used models are
the so-called Claus model [3] and the Gail model [4]. The
Claus model provides cumulative breast cancer risks for
women with different numbers of relatives with breast
cancer or ovarian cancer at different ages. In addition to
the number of FDRs with breast cancer, the Gail model
also takes nonhereditary risk factors into account.
The identification of the inherited breast cancer suscepti-
bility genes, most notably BRCA1 and BRCA2 [5–7], has
greatly improved the possibility of providing distinct esti-
mates of future breast cancer risk in mutation-positive fam-
ilies, and above all has opened up the possibility of
differentiating between carriers with a markedly increased
risk and noncarriers with a population-like risk in these
families. However, the introduction of BRCA1 and
BRCA2 mutation testing in clinical oncogenetic coun-
selling will inevitably lead to bias in the risk estimates if the
same epidemiologically based risk-calculation models are
used in families where BRCA1 and BRCA2 have been
excluded as the causative factor of inherited cancer.
In families with an identified BRCA1 or BRCA2 mutation,
the risk estimate of breast cancer in mutation carriers will
depend on the population on which the calculation is
based and on the way family members were ascertained
(discussed by Dörum and colleagues [8]). Generally
speaking, penetrance estimates of mutation carriers tend
to indicate a higher cumulative risk of breast cancer if
based on a set of high-risk families [9,10] than if based on
a population-based set of mutation carriers not recruited
due to the occurrence of multiple cases of breast cancer
in their families [11–15]. Families identified in oncogenetic
counselling have penetrance estimates of breast cancer
between these two extremes [16].
Despite intense research efforts and the publication of
several potential chromosomal loci [17–22] since and
before the identifications of BRCA1 and BRCA2, no gen-
erally accepted high-penetrant ‘breast cancer gene 3’ has
been identified. A recent study of FDRs of incident breast
cancer cases where BRCA1 and BRCA2 were excluded
indicates that obtaining a complete picture of the remain-
ing molecular genetic factors involved in hereditary breast
cancer may be difficult given the fact that several common
alleles may be involved in a polygenic model, and that
recessive genes are as likely as dominant ones to be
involved in ‘unexplained’ hereditary breast cancer families
[23]. For those families where BRCA1 and BRCA2 muta-
tions are not identified, therefore, data from epidemiologi-
cal studies have, and probably will in the future continue to
have, a strong impact on clinical oncogenetic counselling.
The main purpose of the present study is to estimate rela-
tive and absolute cancer risks in FDRs (i.e. siblings and
parents) of a population-based set of index individuals
with early-onset breast cancer (onset younger than age
41 years), a known family history of cancer, and a known
BRCA1 and BRCA2 mutation status. These estimates are
made to provide data that can be used in the counselling
of individuals in a BRCA1-screened and BRCA2-
screened population.
Materials and methods
During the period 1 January–31 December 1995, a total
of 262 women aged 40 years or younger were diagnosed
with breast cancer in the South Swedish Health Care
Region. After approval was obtained from the ethical com-
mittee at Lund University Hospital, these women were
invited to a population-based screening of BRCA1 and
BRCA2 germline mutations and a survey of their family
history of cancer. Among a total of 234 women screened
for germline mutations, 16 mutation carriers (6.8%) were
initially detected for BRCA1 and five mutation carriers
(2.1%) for BRCA2 [24]. After the publication of the study,
however, an additional mutation was detected in one of
the families: the sister of an index case with a medullary
breast cancer contracted breast cancer and sought onco-
genetic counselling. In this situation, mutation screening
was reiterated in the index individual using denaturating
high-performance liquid chromatography, a more sensitive
method than that previously used (single-stranded confor-
mal polymorphism). A 300T→G germline mutation in
BRCA1 that had escaped previous detection was identi-
fied. The rates of mutation of BRCA1 was thus modified
to 17/234 (7.3%), and the total rate of BRCA mutation
carriers was set to 22/234 (9.4%).
All data regarding cancer diagnoses in cases and rela-
tives in the study were obtained from independent
sources. Children, siblings, parents and their siblings, as
well as grandparents of the index women were identified
for this study by contacting the local revenue authorities
that keep the local census registers. Questionnaire data
from the index individuals were used only to make sure no
relatives were overseen when identifying family members.
Malignant diagnoses of these individuals were obtained
from the regional and national cancer registries. Only
study subjects where diagnoses in FDRs could be
checked-up in the local or national cancer register were
included in the statistical analyses (n=203). Dropouts
were either a result of the index individual not participat-
ing in the mutation analysis or due to the fact that data on
family history could not be traced in Swedish registers,
most frequently because the family was of foreign ances-try. The material has been described in greater detail in a
previous publication [24].
Statistical risk calculations were performed separately on
three sets of FDRs. Index individuals were excluded from
all analyses. The first set of individuals included all FDRs
of identified index individuals without a BRCA1 or BRCA2
germline mutation (n=646). The second analysis group
consisted of a selected group of high-risk individuals with
at least one FDR or second-degree relative with breast
cancer in the same branch of the family, other than relative
to the index woman (n=180). The families of these indi-
viduals were families that would have been considered for
mutation screening of BRCA1 and  BRCA2 if they had
been identified through the ordinary oncogenetic recep-
tion, a clinical unit for oncogenetic counselling jointly run
by the departments of oncology and clinical genetics at
Lund University Hospital. The third set of individuals
included all FDRs of index cases with an identified
BRCA1 or BRCA2 germline mutation (n=82).
Individual family members of index individuals that were
mutation carriers were not uniformly tested for both
BRCA1 and BCRA2, and thus data on the individual
carrier status were not included in the analyses. Data on
cancer incidence not verified in the national or regional
cancer register were accepted for the purpose of identify-
ing individuals with at least one FDR or second-degree
relative with breast cancer other than the index individual,
but not for inclusion in the cohort analysis itself. For
example, if the index individual reported that the maternal
grandmother of an index individual had died from breast
cancer and this could not be verified in the cancer regis-
ter, the mother and all siblings of the index individual were
included in the analysis of high-risk women with one FDR
or second-degree relative with breast cancer other than
the index woman (Fig. 1a). On the contrary, if a paternal
aunt and a sister of the index case were recorded to have
breast cancer, then the father, siblings and children of the
index case were included, but not the mother (Fig.1b).
Because of the small number of mutation-positive index
cases in the study (n=22), calculations of the dominantly
inherited breast cancer susceptibility genes in BRCA1-
positive and BRCA2-positive families (n=82 FDRs) were
not carried out separately, but were pooled in one group.
Calculation of standard incidence ratios
Cancer incidence in relatives of the index cases was
analysed by calculating standardized incidence ratios
(SIRs) with stratification by sex, by calendar year, and by
5-year age groups. Incidence rates from the southern
region of Sweden were used as references. The different
study cohorts were stratified by the index cases’ age of
onset. Individuals in the cohorts were followed from date
of birth until the earliest event of death, of a second
primary cancer diagnosis, of emigration, or of end of study
follow-up (i.e. 31 December 2000).
In standard cohort analyses, the statistical inference is
based on the assumption that the observations are inde-
pendent and Poisson distributed. The Poisson assumption
is not correct if there is a family factor (hereditary or envi-
ronmental), since this means that there is a dependency
between the individuals of a family. The estimate of the
SIR from a standard cohort analysis will be correct even
when a dependency is present between data, but the esti-
mate of its standard error may be too small if the depen-
dency between family members is not taken into account.
Therefore, we have used a sampling-based standard error
when calculating approximate confidence intervals based
on the normal distribution [2].
Calculation of cumulative breast cancer risks
To be able to calculate cumulative breast cancer inci-
dence in mutation carriers in the families where individual
testing had not been performed, we calculated the cumu-
lative breast cancer risk using the following method. Let
SMRE denote the standardized morbidity ratio of individu-
als with exposure E (E can, for instance, indicate the
prevalence of a FDR with breast cancer). The probability
of an individual with exposure E developing breast cancer
before the age of t is then:
P (brca < t | E) = [1 – e (–SMR E · Σ
i, j | tij < t
λij
ref · ∆tij )]
where λij
ref is the age-specific and calendar year-specific
breast cancer incidence in the reference population, and
∆tij is the time in age interval i and calendar year j.
The cumulative risk for a BRCA1 or  BRCA2  mutation
carrier was calculated using the estimate of the cumulative
risk for FDRs of the index women with a BRCA1 or
BRCA2 mutation:
P(brca < t | FDR of index women) = 
0.5[P(brca < t | no mutation)] + 
0.5[P(brca < t | BRCA1 or BRCA2 mutation)]
⇔
P(brca < t | BRCA1 or BRCA2 mutation) = 
{P(brca < t | FDR of index women) – 
0.5[P(brca < t | no mutation)]} / 0.5
The estimation of the standard errors of the cumulative
risks was calculated using Gauss approximation. Cumula-
tive incidences and confidence intervals were calculated
in 5-year intervals.
Stata 6.0 statistical software was used for all statistical
analyses [25].
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The mutation status and the family history according to the
criteria for inclusion in the study (i.e. confirmed data on
cancer incidence among siblings and parents of the index
individual) were known for 203 out of 262 index individu-
als (77.5%). The families of these index individuals
included 728 FDRs. In addition, 804 female second-
degree relatives (paternal and maternal aunts and grand-
mothers) of the index individuals were identified. In total,
22 families where BRCA1 or  BRCA2 mutations were
identified in index individuals (17 families with BRCA1
mutations and five families with BRCA2 mutations) and
181 families without mutations were included in the study.
Out of the families with no BRCA1 or BRCA2 mutation,
70 had a family history with at least one additional case of
breast cancer in a FDR or a second-degree relative of the
index individual; by definition, a woman younger than the
age of 41 years with breast cancer (Fig.1a,b).
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Figure 1
Pedigrees indicating which individuals were included in the BRCA nonassociated high-risk group. The cohort of high-risk individuals was selected
based on the prevalence of at least one additional case of breast cancer apart from the index woman in those families. In these two hypothetical
families, (a) and (b), individuals affected with breast cancer appear in greyish colour. Individuals included in the analyses are marked with a black dot.
Index woman, breast
cancer <41, years of age
Maternal grandmother of
index woman Affected with
breast cancer at age 75
Index woman, breast
cancer <41, years of age
Ovarian cancer at age 45
in sister of index woman.
Breast cancer at an
unknown age in paternal
aunt of index woman.
(a)
(b)Available online http://breast-cancer-research.com/content/5/6/R175
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Table 1
Cancer incidences in first-degree relatives of BRCA1/BRCA2 noncarriers
Standardized 95% confidence
ICD-7 Site Observed (n) Expected (n) incidence ratio interval
140–209 All malignant tumours 120 82.3 1.5 1.2–1.7
Non-170 All malignant tumours except breast 91 69.9 1.3 1.1–1.6
140 Lip 1 0.50 2.0 0.05–11.1
141 + 143–144 Cavum oris 0 0.56 0 0–6.6
142 Salivary glands 1 0.31 3.2 0.08–17.8
145–148 Throat 0 0.40 0 0–9.1
150 Oesophagus 0 0.53 0 0–6.9
151 Stomach 2 2.8 0.71 0.09–2.6
153 Large bowel 5 5.6 0.89 0.29–2.1
154 Rectum 6 3.8 1.6 0.58–3.5
1550 Liver 1 0.61 1.6 0.04–9.1
1551–1559 Gall tract 1 1.2 0.85 0.02–4.8
157 Pancreas 0 2.3 0 0–1.6
160 Nose and sinuses 0 0.18 0 0–20.4
161 Larynx 0 0.50 0 0–7.3
1620–1621 Trachea and lung 8 6.6 1.2 0.53–2.4
1622 Pleura 0 0.21 0 0–17.8
170 Breast 29 12.4 2.3 1.6–3.4
171 Cervix uteri 5 1.5 3.3 1.1–7.6
172 + 174 Uterine corpus 2 3.0 0.68 0.80–2.4
175 Ovaries 3 2.5 1.2 0.24–3.5
176 Vulva, vagina 0 0.32 0.0 0–11.7
177 Prostate 17 9.9 1.7 1.0–2.8
178 Testes 0 0.61 0 0–6.0
180 Kidneys 3 3.2 0.93 0.19–2.7
181 Bladder and urinary tract 3 3.9 0.76 0.16–2.2
190 Melanoma 5 3.2 1.5 0.49–3.5
191 Skin, nonmelanoma 6 2.1 2.8 1.0–6.1
193 Central nervous system 6 3.7 1.6 0.60–3.6
194 Thyroid 0 1.53 0 0–2.4
196–197 Bone, connective tissue 0 0.79 0 0–4.7
200 + 202 Non-Hodgkin’s lymphoma 4 3.0 1.4 0.37–3.4
201 Hodgkin’s disease 2 0.59 3.4 0.41–12.2
203 Myeloma 0 1.2 0 0–2.9
Acute leukaemia 3 0.76 4.0 0.82–11.6
2041 Chronic lymphocytic leukaemia  1 0.84 1.2 0.03–6.6
2051 Chronic myelogenous leukaemia 0 0.25 0 0–14.9
208 Polycytaemia vera 0 0.34 0 0–10.8
Age 0–79 years; n = 646; 25,244.0 person-years; 1958–2000.Relative cancer incidence in FDRs of BRCA
nonmutation carriers (Table 1)
The incidence of all malignant tumours was increased
among FDRs of women without a BRCA1 or  BRCA2
mutation (n = 646) (observed cases = 120 versus
expected cases = 82.3, SIR = 1.5, 95% confidence inter-
val [CI]=1.2–1.7). The incidence of all malignant tumours
excluding breast cancer was also significantly elevated
(observed cases = 91 versus expected cases = 69.9,
SIR=1.3, 95% CI=1.1–1.6). The risk of breast cancer
among FDRs of non-BRCA1/non-BRCA2 mutation carri-
ers was more than doubled (observed cases = 29 versus
expected cases = 12.4, SIR = 2.3, 95% CI = 1.6–3.4). In
addition, the SIR of prostate cancer was increased
(observed cases = 17 versus expected cases=9.9,
SIR=1.7, 95% CI=1.0–2.8), as was the SIR of cervix
cancer (observed cases=5 versus expected cases=1.5,
SIR=3.3, 95% CI=1.1–7.6) and of nonmelanoma skin
cancer (observed cases=6 versus expected cases=2.1,
SIR=2.8, 95% CI=1.0–6.1).
The FDRs of non-BRCA1/non-BRCA2 mutation carriers
were subdivided into groups on the basis of the age of the
index case. In FDRs of index women aged younger than
36 years (n=184) breast cancer was increased more
than threefold (observed cases=9 versus expected
cases=2.8, SIR=3.2, 95% CI=1.5–6.1) compared with
FDRs of index women aged 36 years and older (n=462),
among which the increase was only twofold (observed
cases=20 versus expected cases=9.6, SIR=2.1, 95%
CI=1.3–3.2). Furthermore, the increase of prostate
cancer appeared to be confined to the FDRs of index
women younger than the age of 36 years (observed
cases=9 versus expected cases=2.0, SIR=4.4, 95%
CI=2.0–8.4). Among FDRs of index women aged
36 years or older, no elevation in prostate cancer risk was
observed (observed cases = 8 versus expected cases =
7.8, SIR=1.0, 95% CI=0.44–2.0). In female second-
degree relatives of BRCA nonmutation carriers (n=746)
the breast cancer risk was not significantly elevated com-
pared with what could be expected for the population
(observed cases=48 versus expected cases = 39.4, SIR =
1.2, 95% CI = 0.90–1.6).
Individuals with a positive family history of breast
cancer (Table 2)
Among individuals without a BRCA1 or BRCA2 muta-
tion in the family but with at least one case of breast
cancer in a FDR or a second-degree relative other than
the index case (n=180, related to 61 index individuals),
the SIR of all malignant tumours was elevated (observed
cases=43 versus expected cases=18.5, SIR=2.3,
95% CI=1.6–3.1). When breast cancer incidence was
excluded, the risk of cancer was still increased in this
group (observed cases=29 versus expected
cases=15.9, SIR=1.8, 95% CI=1.2–2.6). In this
group, breast cancer (observed cases=14 versus
expected cases=2.6, SIR=5.3, 95% CI=2.9–9.0)
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Table 2
Cancer incidence in first-degree relatives of index cases with breast cancer younger than age 41 but no BRCA1/BRCA2 germline
mutation, and at least one additional case of breast cancer in a first-degree or second-degree relative
Standardized 95%
ICD-7 Site Observed (n) Expected (n) incidence ratio confidence interval
140–209 All malignant tumours 43 18.5 2.3 1.6–3.1
Non-170 All malignant tumours except breast  29 15.9 1.8 1.2–2.6
153 Large bowel 1 1.2 0.82 0.02–4.6
154 Rectum 2 0.82 2.4 0.30–8.8
162 Trachea and lung 3 1.5 2.0 0.42–5.9
170 Breast 14 2.6 5.3 2.9–9.0
171 Cervix uteri 2 0.39 5.1 0.62–18.5
175 Ovaries 1 0.50 2.0 0.05–11.0
177 Prostate 6 2.4 2.5 0.91–5.4
180 Kidney 2 0.74 2.7 0.33–9.8
181 Bladder and urinary tract 2 0.93 2.1 0.26–7.8
191 Skin nonmelanoma 1 0.50 2.0 0.05–11.2
193 Central nervous system 2 0.86 2.3 0.28–8.4
200 + 202 Non-Hodgkin’s lymphoma 3 0.66 4.5 0.94–13.3
Age 0–79 years; n = 180; 6885.2 person-years; 1958–2000.was elevated, and there were also nonsignificant
increases of prostate cancer (observed cases=6
versus expected cases=2.4, SIR=2.5, 95%
CI=0.91–5.4) and non-Hodgkin’s lymphoma (NHL)
(observed cases=3 versus expected cases=0.66,
SIR=4.5, 95% CI=0.94–13.3).
FDRs of BRCA mutation carriers (Table 3)
Among FDRs of BRCA1 and BRCA2 mutation carriers
(n=82), the SIR of all malignant tumours was increased
(observed cases=20 versus expected cases=7.3,
SIR=2.7, 95% CI=1.7–4.2). When breast cancer cases
were excluded, the increase diminished but was still statis-
tically significant (observed cases=12 versus expected
cases=6.2, SIR=1.9, 95% CI=1.0–1.6). When it came
to individual diagnoses, breast cancer (observed
cases=8 versus expected cases=1.1, SIR=7.2, 95%
CI=3.1–14.3) and ovarian cancer (observed cases=3
versus expected cases=0.20, SIR=14.9, 95%
CI=3.1–43.7) were observed more frequently than
expected. In female second-degree relatives of BRCA1
and  BRCA2 mutation carriers (n=61), breast cancer
(observed cases=8 versus expected cases=2.8,
SIR=2.8, 95% CI=1.2–5.6) and ovarian cancer
(observed cases=4 versus expected cases=0.64,
SIR=6.2, 95% CI=1.7-16.0) were also elevated.
Cumulative breast cancer risks
The cumulative incidence of breast cancer at ages 50 and
70 years among FDRs of index women without an identi-
fied  BRCA1 or  BRCA2 germline mutation was 3.6%
(95% CI=1.3–5.7%) and 12.8% (95% CI=6.5–15.7%),
respectively (Fig.2a). The cumulative incidence of breast
cancer in the group of individuals without a BRCA1 muta-
tion or a BRCA2 mutation but with at least one FDR or
second-degree relative with breast cancer other than the
index case was 6.3% (95% CI=3.2–10.9%) at age
50 years and 21.1% (95% CI=11.1–34.7%) at age
70 years (Fig.2b). The cumulative breast cancer incidence
in the female population of the South Swedish Health
Care Region was 1.5% at age 50 years and 5.3% at age
70 years, significantly lower compared with all study
groups (Figs2a–d). The cumulative incidence of breast
cancer at ages 50 and 70 years among FDRs of index
individuals with an identifiable BRCA1 or BRCA2 muta-
tion was 17.2% (95% CI=6.7–33.7%) and 27.7% (95%
CI=8.2–54.4%), respectively (Fig.2c), translating to a
32.9% (95% CI=8.2–62.1%) and 50.2% (95%
CI=14.9–100%) risk of breast cancer among BRCA1 or
BRCA2 mutation carriers (Fig.2d).
Discussion
In the present paper we present a population-based
overview of the hereditary and familial risks of cancer in
relatives of early-onset breast cancer cases from southern
Sweden. All individuals and all diagnoses included in the
statistical estimations were verified from independent and
reliable data sources. In several previous studies of familial
risk of cancer that are frequently used in oncogenetic
counselling of cancer risk in breast cancer families,
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Table 3
Cancer incidence in first-degree relatives of BRCA1/BRCA2 carriers
Standardized 95%
ICD-7 Site Observed (n) Expected (n) incidence ratio confidence interval
140–209 All malignant tumours 20 7.3 2.7 1.7–4.2
Non-170 All malignant tumours except breast 12 6.2 1.9 1.0–1.6
151 Stomach 0 0.21 0 0–17.3
153 Large bowel 0 0.44 0 0–8.3
157 Pancreas 1 0.17 5.8 0.15–32.2
170 Breast 8 1.1 7.2 3.1–14.3
171 Cervix uteri 0 0.17 0 0–21.5
175 Ovaries 3 0.20 14.9 3.1–43.7
176 Vulva, vagina 1 0.02 45.6 1.1–254
177 Prostate 2 0.82 2.4 0.30–8.8
190 Melanoma 1 0.36 2.8 0.70–15.6
191 Skin, nonmelanoma 0 0.19 0 0–19.8
193 Central nervous system 1 0.40 2.5 0.06–13.9
194 Thyroid 1 0.17 5.9 0.15–33.0
Age 0–79 years; n = 82; 3106.4 person-years; 1958–2000.unknown numbers of unidentified families with BRCA1
and BRCA2 mutations are hidden among other families.
This will introduce bias in the counselling situation if data
from such studies are utilized to estimate breast cancer
risk in individuals from families where BRCA1 and BRCA2
have been excluded as the disease-causing factor, a com-
monplace procedure nowadays in oncogenetic clinics
worldwide. Providing clinically useful data for the large
group of BRCA1-negative and BRCA2-negative families
seeking oncogenetic counselling has been the main
objective of the present study. Although the size of study
sample may seem limited, the quality of data, the high
inclusion rate and the thorough BRCA screening that was
performed justifies certain conclusions to be drawn from
the dataset.
One  BRCA1 mutation carrier was detected due to
reanalysis of that particular case with a more sensitive
technique. Since one of the main aims of the study was to
analyse cancer incidence in BRCA1 and BRCA2 noncar-
riers, we were not willing to include a known mutation
carrier in that study group even if the detection of this
Breast Cancer Research    Vol 5 No 6 Loman et al.
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Figure 2
Cumulative breast cancer incidences up to the age of 70 years of the different study cohorts. (a) Cumulative incidence of breast cancer (solid line)
(dotted lines, 95% confidence interval) for first-degree relatives of breast cancer susceptibility gene 1 (BRCA1) and breast cancer susceptibility
gene 2 (BRCA2) mutation noncarriers younger than age 41 years. A general female South Swedish population is added for comparison (dashed
line). (b) Cumulative incidence of breast cancer (solid line) (dotted lines, 95% confidence interval) for women with at least two first-degree relatives
with breast cancer, of which one is an index individual diagnosed younger than age 41 years and is without an identified BRCA1/BRCA2 germline
mutation. A general female South Swedish population is added for comparison (dashed line). (c) Cumulative incidence of breast cancer (solid line)
(dotted lines, 95% confidence interval) for first-degree relatives of BRCA1 and BRCA2 mutation carriers younger than age 41 years. A general
female South Swedish population is added for comparison (dashed line). (d) Calculated cumulative incidence of breast cancer (solid line) (dotted
lines, 95% confidence interval) for BRCA1 and BRCA2 mutation carriers younger than age 41 years. A general female South Swedish population is
added for comparison (dashed line).
(a)                                                                                                                      (b)
(c)                                                                                                                      (d)case was not strictly population based. Second, denatu-
rating high-performance liquid chromatography was intro-
duced to replace the single-stranded conformal
polymorphism technique in our laboratory when about
one-half of the cases were analysed. The intention was to
increase the sensitivity of the mutation screening. It was
therefore reasonable to accept its use in an additional
case.
Regarding FDRs of non-BRCA1/non-BRCA2-mutation
carriers, the main findings were increased risks of breast
cancer, of prostate cancer, of cervix cancer and of non-
melanoma skin cancer. The risks seemed to depend on
the age of the index individual at the time of diagnosis, and
were higher for breast cancer in FDRs of index individuals
diagnosed with breast cancer younger than the age of
36 years compared with FDRs of index individuals diag-
nosed between the ages of 36 and 41 years. The risks of
prostate cancer and of skin cancer were only elevated in
FDRs of index individuals younger than the age of
36 years. The increase in cervix cancer risk was not signifi-
cant in any of the subgroups of FDRs of index cases
younger or older than the age of 36 years (data not
shown). This finding might indicate an association
between very early-onset breast cancer and one or several
of prostate cancer, of nonmelanoma skin cancer and, pos-
sibly, of cervix cancer.
In the literature, partly conflicting data regarding the asso-
ciation between breast cancer and prostate cancer have
been presented. In two studies of relatives of prostate
cancer patients, no excess risks of breast cancer or any
other nonprostate cancers were identified [26,27]. Other
studies have indicated an association. In an American
case–cohort study of 981 cases with prostate cancer and
1315 controls, an association between prostate cancer
and breast cancer in sisters was identified, but this was
not the case in mothers of prostate cancer cases [28]. In a
study of families from Utah, a small but statistically signifi-
cant increase in prostate cancer was observed in relatives
of breast cancer patients [29]. Finally, in Iceland, relatives
of breast cancer patients were subject to a 1.5-fold
increase in prostate cancer risk [30], an increase most
probably attributable to carriers of the Icelandic BRCA2
founder mutation.
Since BRCA1 and BRCA2 were characterized, prostate
cancer has been linked to breast cancer through these
genes. In some studies on mutation carriers, BRCA1 and
BRCA2 have been associated with increased risk of
prostate cancer [9,31]. It has been claimed that BRCA2 is
associated with a sevenfold increase in prostate cancer
risk in mutation carriers compared with that in the general
population [31]. The increased risk of prostate cancer in
relatives of BRCA2 mutation carriers has also been seen
in a previous study from our institute [32].
Several of the aforementioned studies suggest an associ-
ation between breast cancer and prostate cancer that
could well be mediated through an increased risk of both
malignancies in BRCA2 mutation carriers. The present
study suggests that there may be a residual association
not mediated through this gene in families with very early-
onset breast cancer. A possible explanation could be that
we have overlooked a number of mutation carriers during
mutation screening. Sensitivity of mutation screening is
not 100%; it is thus probable that not all mutation carriers
in the material were identified, and that the over-risk of
prostate cancer could be due to undetected BRCA2 fami-
lies in the dataset. It should be noted, however, that if a
significant number of BRCA1 mutation carriers have been
overlooked during mutation screening, then one would
expect to observe an excess of ovarian cancer cases in
the remaining families; this was not the case. The observa-
tion concerning the increased risk of prostate cancer in
FDRs of breast cancer cases younger than the age of
36 years needs further study to be confirmed.
An association between breast cancer and nonmelanoma
skin cancer was previously reported in a study on BRCA1-
associated families from Southern Sweden [32]. To our
knowledge, such an association has not been reported
elsewhere.
BRCA mutations are generally detected in only a fraction
of the families that are offered mutation screening. It is of
great clinical importance to be able to provide reliable esti-
mates of cancer risk among individuals of those mutation-
negative families for which mutation status will provide no
further information; at our institute, almost three-quarters
of the analysed families (unpublished observation). To
explore this group further, we selected a group of FDRs of
nonmutation carriers who had at least one additional FDR
or second-degree relative in the same side of the pedigree
with breast cancer. In this selected subgroup of BRCA1
and  BRCA2 mutation-negative families, which corre-
sponds to families offered clinical mutation screening
according to the aforementioned criteria, we observed a
significantly increased greater than twofold risk for all
malignant tumours and a fivefold increased risk of breast
cancer. Prostate cancer and NHL were frequent, but were
not statistically significantly increased. A similar observa-
tion regarding NHL was made previously in a large family
material from Utah, where the risk of NHL was increased
in relatives of cases of early-onset breast cancer (onset
younger than 50 years of age) [29].
We noted that germline mutations in BRCA1 and
BRCA2 do not appear to be associated with any major
risk increase in any malignant diagnoses apart from
breast cancer and ovarian cancer. Furthermore, all
observed cases of ovarian cancer were seen in first-
degree relatives of BRCA1 mutation carriers (n=63);
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FDRs of BRCA2 mutation carriers or in individuals
without a BRCA1 or  BRCA2 germline mutation. This
observation regarding ovarian cancer in BRCA2 mutation
carriers fits well with a previous observation that we made
in an earlier study on a mainly separate set of BRCA1-
associated and BRCA2-associated families. In that study,
we did not observe any increased risk of ovarian cancer
in members of BRCA2-mutation families if the cases that
led to the identification of the families were excluded from
the analysis [32]. Interestingly, the increased risk of
prostate cancer and colorectal cancer that has been
observed in some studies of BRCA mutation carriers
[9,32,33] was not observed in the present material. The
fact that prostate cancer and colorectal cancer were not
excessive in the material could be due to the relatively
small size of the study and to insufficient statistical power
and too few years of follow-up in FDRs at relevant ages.
However, it may also be an important observation with
implications for male mutation carriers in BRCA1 and
BRCA2 mutation-positive families. This situation might
change with prolonged follow-up.
Considering the fact that the excess risk of ovarian cancer
in FDRs of mutation carriers was picked up in the present
study, it does seem justified to draw the conclusion that
the risks of prostate cancer and of colorectal cancer up to
the age of 79 years in BRCA1 and BRCA2 families are
significantly lower than the risk of ovarian cancer in FDRs
of BRCA mutation carriers. This may support the opinion
that the need for controls aiming at early detection of
these diagnoses in mutation carriers may not be clinically
warranted. Finally, a cumulative breast cancer incidence at
ages 50 and 70 years was generated for mutation carriers
of BRCA1 and BRCA2, and was found to be 32.9% and
50.2%, respectively. This moderate risk estimate fits well
into the previously observed pattern of extremely high pen-
etrance estimates based on selected high-risk families
[9,10], and more moderate estimations stemming from
materials that are population based [11–14]. However,
since the number of included relatives of mutation carriers
is relatively limited, the estimate must be regarded with
some caution. This is especially true for the incidence
older than age 50 years, where a limited number of
person-years were observed (n=651) and only two breast
cancers were recorded. Most of these person-years refer
to mothers of the index individuals.
The cumulative breast cancer risk at ages 50 and 70 years
was analysed in the three groups of FDRs. The practice of
using incident breast cancer cases when estimating
cumulative breast cancer risk has been criticized due to
the risk of overestimation since nongenetic risk factors are
likely to be over-represented in such series [34]. We have
tried to minimize this bias by excluding index individuals
from all estimations. In the present study of cumulative
breast cancer incidence, BRCA1 and BRCA2 mutation
carriers were analysed jointly because of the limited
number of available cases. This may generate a less infor-
mative penetrance estimate related to the fact that the
penetrance of breast cancer in BRCA1 and BRCA2 muta-
tion carriers may differ due to differences in gene-specific
properties regarding breast cancer risk. In addition, the
number of cases analysed may be considered low, but the
set of BRCA mutation carriers upon which the estimate is
based is larger than or similar to those of several previous
studies in the field [13,14,35]. The cumulative incidence
curves of the different study groups suggest that the
annual risk of breast cancer in BRCA1 and  BRCA2 is
largest premenopausally, and that this may differ from
what might be expected in genes that are detected in the
future, which may display a risk that is approximately the
same before and after menopause.
Several genes and chromosomal loci have been sug-
gested to be the molecular genetic basis for the
increased risk of breast cancer in non-BRCA1/non-
BRCA2 breast cancer families. Genes such as p53
[36–38], CHK2 [39,40], PTEN [41] and CDKN2A/p16
[42] may be associated with some of the remaining high-
risk families. In addition, there is some evidence that fam-
ilies with Peutz–Jeghers syndrome and a mutation in
LKB1 [43] have an increased risk of breast cancer and
ovarian tumours [44,45], even if the major clinical conse-
quences of this syndrome are related to the gastroin-
testinal tract, making it more likely that such families are
identified through these manifestations than as breast
cancer or ovarian cancer families. The genes BARD1
[46], RAD51 [47], BACH1 [48] and ATM [49] are addi-
tional genes that have been suggested to be associated
with hereditary breast cancer. However, their contribu-
tion is likely to be small. Germline mutations in the
E-cadherin gene are associated with not only lobular
breast cancer risk, but also with risk of diffuse stomach
cancer, and they may also contribute to inherited breast
cancer risk [50].
Hitherto unidentified genes have, based on linkage analy-
sis of limited chromosomal regions or genome-wide scan-
ning, been suggested to be located on chromosomal loci
on 2q [17], 6q [18], 8p [19,20], and 13q21 [21]. In a UK
study of 112 ovarian and breast cancer–ovarian cancer
families, most breast cancer–ovarian cancer and ovarian
cancer families were likely to be associated with BRCA1
and BRCA2 [51]. A chromosomal locus on 3p25-p22 has
been linked to families with an increased prevalence of
ovarian cancer in a study on Japanese ovarian cancer fam-
ilies [22]. These chromosomal loci may harbour genes
that, after future identification and characterization, may
prove useful in the investigation and counselling of individ-
uals seeking medical advice for a suspicion of an
increased hereditary risk of breast cancer.
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be an associated risk on one or more future breast cancer
susceptibility genes. Until these genes are molecularly and
genetically characterized, we shall have to rely on epidemi-
ological studies such as the present one for the estimation
of breast cancer risk in healthy relatives of breast cancer
patients without mutations in known susceptibility genes.
Conclusions
Breast cancer risk in FDRs of early-onset breast cancer
cases is elevated irrespective of the BRCA mutation
status. The risk appears to increase with decreasing age
and increasing number of affected relatives. In relatives of
breast cancer cases younger than age 36 years, an asso-
ciation with prostate cancer and nonmelanoma skin
cancer is suggested. There is no indication of an
increased risk of ovarian cancer in families without a
BRCA mutation. The cumulative breast cancer risk at age
50 years is likely to be higher in FDRs of BRCA mutation
carriers compared with FDRs of carriers of hitherto
unidentified breast cancer susceptibility genes.
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